| scholarly article | Q13442814 |
| P356 | DOI | 10.1124/DMD.108.025981 |
| P698 | PubMed publication ID | 19420130 |
| P2093 | author name string | Robert M Knabb | |
| Kan He | |||
| Lifei Wang | |||
| Donglu Zhang | |||
| Feng Hao | |||
| James Mitroka | |||
| W Griffith Humphreys | |||
| Charles Frost | |||
| Nirmala Raghavan | |||
| Scott J Grossman | |||
| Brad D Maxwell | |||
| Alan Schuster | |||
| Zheming Gu | |||
| P433 | issue | 8 | |
| P921 | main subject | apixaban | Q414462 |
| P304 | page(s) | 1738-1748 | |
| P577 | publication date | 2009-05-06 | |
| P1433 | published in | Drug Metabolism and Disposition | Q1261140 |
| P1476 | title | Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans. | |
| P478 | volume | 37 |
| Q92028447 | Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review |
| Q38020739 | Apixaban: a novel oral inhibitor of factor Xa. |
| Q38107180 | Apixaban: a review of its use for reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation |
| Q38017736 | Apixaban: a review of its use in the prevention of venous thromboembolism after knee or hip replacement surgery |
| Q28468389 | Drug-induced liver injury: Towards early prediction and risk stratification |
| Q53218072 | Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa. |
| Q37653181 | Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects |
| Q35557449 | Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor |
| Q34554473 | Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban |
| Q83067930 | Factor Xa and thrombin as targets for new oral anticoagulants |
| Q30662550 | Identification of drug metabolites in human plasma or serum integrating metabolite prediction, LC-HRMS and untargeted data processing |
| Q38613869 | Laboratory measurement of the direct oral anticoagulants |
| Q26766303 | Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation Therapy |
| Q48248862 | Management of patients on antithrombotic agents undergoing emergency and elective endoscopy: joint Asian Pacific Association of Gastroenterology (APAGE) and Asian Pacific Society for Digestive Endoscopy (APSDE) practice guidelines |
| Q43256203 | Metabolism, pharmacokinetics and pharmacodynamics of the factor Xa inhibitor apixaban in rabbits |
| Q38777127 | Pharmacodynamics, pharmacokinetics and clinical efficacy of apixaban in the treatment of thrombosis |
| Q23919667 | Pharmacogenetics, pharmacogenomics, and individualized medicine |
| Q60047181 | Pharmacokinetics and Pharmacodynamics of an Oral Formulation of Apixaban in Horses After Oral and Intravenous Administration |
| Q49850586 | Population pharmacokinetics and pharmacogenomics of apixaban in Japanese adult patients with atrial fibrillation. |
| Q37841256 | Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor |
| Q52838335 | Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor. |
| Q34671648 | Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism |
| Q37879330 | Renal profiles of anticoagulants |
| Q27001191 | Review: toxicometabolomics |
| Q36933789 | Role of apixaban (eliquis) in the treatment and prevention of thromboembolic disease |
| Q26764874 | Safety of apixaban for venous thromboembolism prophylaxis: the evidence to date |
| Q37388373 | Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects |
| Q35093416 | Structural elucidation of rat biliary metabolites of corynoxeine and their quantification using LC-MS(n). |
| Q38105619 | The safety and efficacy of apixaban : where do we stand in 2013? |
| Q92977571 | Unexpected excessive apixaban exposure: case report of a patient with polymorphisms of multiple apixaban elimination pathways |
Search more.